PanGen Biotech Inc. (KOSDAQ:222110)

PanGen Biotech Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3,186	1,430	45.4	838.28	8,901	8,139
Short-Term Investments	10,047	10,002	149.24	2	15,199	10,550
Cash & Short-Term Investments	13,233	11,432	194.64	840.28	24,100	18,689
Cash Growth	121.05%	5773.48%	-76.84%	-96.51%	28.95%	-23.29%
Accounts Receivable	2,111	2,959	2,208	689.81	1,089	535.34
Other Receivables	200	51.8	8.54	221.29	241.03	176.87
Receivables	2,311	3,261	2,330	974.1	1,393	775.21
Inventory	6,874	6,001	6,925	6,630	4,373	3,764
Prepaid Expenses	35.37	53.96	58.91	71.41	21.39	15.49
Other Current Assets	883.96	20.35	333.62	60.91	1,267	847.87
Total Current Assets	23,338	20,768	9,843	8,576	31,154	24,092
Property, Plant & Equipment	5,811	5,805	6,240	6,608	6,748	6,029
Long-Term Investments	0	0	0	0	-0	0
Other Intangible Assets	951.86	785.13	879.93	269.63	313.41	271.58
Long-Term Deferred Charges	2,130	2,622	3,278	3,933	4,589	5,244
Other Long-Term Assets	533.58	564.14	501.5	1,287	473.47	673.02
Total Assets	32,765	30,545	20,741	20,674	43,277	36,309
Accounts Payable	264.32	423.33	298.82	255.48	381.91	296.57
Accrued Expenses	179.79	-	-	-	-	-
Short-Term Debt	923.03	816.3	2,014	-	18,692	18,399
Current Portion of Leases	0.87	1.84	1.69	1.56	1.43	-
Other Current Liabilities	1,371	1,657	3,396	872.49	811.14	1,395
Total Current Liabilities	2,739	2,899	5,711	1,130	19,886	20,091
Long-Term Leases	-	0.39	2.24	3.93	5.49	-
Pension & Post-Retirement Benefits	-	2,707	2,432	2,114	2,171	1,930
Other Long-Term Liabilities	-	30	30	206.41	116.22	77.31
Total Liabilities	2,739	5,636	8,175	3,454	22,179	22,098
Common Stock	6,747	6,449	5,339	5,339	5,336	4,821
Additional Paid-In Capital	10,176	67,712	57,402	57,402	57,371	47,840
Retained Earnings	11,799	-49,953	-50,876	-46,210	-42,062	-38,680
Comprehensive Income & Other	1,303	700.82	700.82	688.64	452.86	229.89
Total Common Equity	30,026	24,909	12,566	17,219	21,098	14,211
Shareholders' Equity	30,026	24,909	12,566	17,219	21,098	14,211
Total Liabilities & Equity	32,765	30,545	20,741	20,674	43,277	36,309
Total Debt	923.89	818.54	2,018	5.49	18,699	18,399
Net Cash (Debt)	12,310	10,614	-1,823	834.79	5,402	290.4
Net Cash Growth	232.19%	-	-	-84.55%	1760.05%	-95.84%
Net Cash Per Share	950.70	927.83	-170.60	78.21	528.69	30.13
Filing Date Shares Outstanding	13.64	12.9	10.68	10.68	10.67	9.64
Total Common Shares Outstanding	13.64	12.9	10.68	10.68	10.67	9.64
Working Capital	20,600	17,869	4,132	7,447	11,267	4,001
Book Value Per Share	2201.42	1931.18	1176.85	1612.67	1976.95	1473.91
Tangible Book Value	29,074	24,124	11,686	16,950	20,784	13,940
Tangible Book Value Per Share	2131.63	1870.31	1094.44	1587.42	1947.58	1445.75
Land	1,174	1,174	1,174	1,174	1,174	1,004
Buildings	3,909	3,909	3,909	3,909	3,909	3,456
Machinery	12,050	11,766	11,545	11,434	10,381	9,811
Construction In Progress	112.7	-	125.36	-	332.66	1.11

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.